Sarepta Gene Therapy: Second Patient Death
- Sarepta Therapeutics on Sunday announced it is indeed suspending shipments of its Elevidys gene therapy for Duchenne muscular dystrophy to patients who are no longer able to walk.
- The first death, involving a 16-year-old boy, was disclosed in March.
- The company is now collaborating with experts to develop an improved immunosuppressive regimen.
Sarepta Therapeutics has halted shipments of its Elevidys gene therapy following a second patient death linked to acute liver failure. This critical action directly impacts non-ambulatory Duchenne muscular dystrophy patients, highlighting the severity of the situation. The company is now working with experts on an enhanced immunosuppressive regimen, aiming to boost patient safety. The deaths underscore the challenges inherent in advanced gene therapy, particularly for those with progressed stages of the disease. News Directory 3 keeps you informed on breakthroughs in medical research. Sarepta plans to discuss the new regimen with the FDA to ensure more robust safety protocols. Discover what’s next as Sarepta collaborates on a safer future for Duchenne muscular dystrophy treatments.
Sarepta Halts Duchenne gene Therapy After Deaths
Updated June 15, 2025
Sarepta Therapeutics on Sunday announced it is indeed suspending shipments of its Elevidys gene therapy for Duchenne muscular dystrophy to patients who are no longer able to walk. This decision follows the death of a second patient who received the treatment.
The first death, involving a 16-year-old boy, was disclosed in March. Both fatalities resulted from acute liver failure, a known side effect associated with some gene therapies. Sarepta noted that both patients were non-ambulatory, meaning their Duchenne muscular dystrophy had progressed to the point where they required wheelchair assistance. Most children with Duchenne lose the ability to walk by adolescence, highlighting the advanced stage of the disease in these cases.
The company is now collaborating with experts to develop an improved immunosuppressive regimen. The goal is to make Elevidys safer for non-ambulatory patients. Sarepta plans to discuss this proposed regimen with the Food and Drug Administration.
What’s next
Sarepta will work with the FDA to refine the treatment protocol, focusing on enhanced safety measures for patients with advanced Duchenne muscular dystrophy before resuming shipments of the gene therapy.